Quick Answer
Travere Therapeutics, Inc. reported Stockholders Equity of $114.83 million for the year ending 2025.
- Travere Therapeutics, Inc. showed an increase of +94.4% in Stockholders Equity from 2024 to 2025.
- This data is from Travere Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$5.80 million | Q1 2014: -$35.39 million | Q2 2014: $1.07 million | Q3 2014: -$10.19 million | Q1 2015: $168.57 million | Q2 2015: $150.78 million | Q3 2015: $291.01 million | Q1 2016: $319.23 million | Q2 2016: $314.37 million | Q3 2016: $307.60 million | Q1 2017: $300.94 million | Q2 2017: $295.83 million | Q3 2017: $304.52 million | Q1 2018: $299.48 million | Q2 2018: $287.99 million | Q3 2018: $319.07 million | Q1 2019: $285.71 million | Q2 2019: $277.09 million | Q3 2019: $245.96 million | Q1 2020: $225.75 million | Q2 2020: $318.65 million | Q3 2020: $301.41 million | Q1 2021: $362.69 million | Q2 2021: $332.30 million | Q3 2021: $307.37 million | Q1 2022: $208.14 million | Q2 2022: $156.71 million | Q3 2022: $100.68 million | Q1 2023: $189.14 million | Q2 2023: $116.49 million | Q3 2023: $279.77 million | Q1 2024: $74.07 million | Q2 2024: $15.15 million | Q3 2024: -$30.45 million | Q1 2025: $32.82 million | Q2 2025: $32.75 million | Q3 2025: $73.56 million.
- Over the full 14 years of available data (2012 to 2025), Travere Therapeutics, Inc.'s Stockholders Equity has grown by 3,469.4%.
- Historical annual values: Fiscal year 2025: $114.83 million | Fiscal year 2024: $59.08 million | Fiscal year 2023: $200.81 million | Fiscal year 2022: $42.85 million | Fiscal year 2021: $302.11 million | Fiscal year 2020: $211.21 million | Fiscal year 2019: $221.20 million | Fiscal year 2018: $318.25 million | Fiscal year 2017: $293.13 million | Fiscal year 2016: $307.77 million | Fiscal year 2015: $299.97 million | Fiscal year 2014: -$37.25 million | Fiscal year 2013: -$19.67 million | Fiscal year 2012: -$3.41 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: